PepJunkie Home of the Peptonauts
More

Peptide Atlas · Peptide

SS-31

SS-31 (elamipretide) is a mitochondria-targeted compound that binds with high affinity to cardiolipin, a phospholipid of the inner mitochondrial membrane required for cristae formation.

What the evidence says

six tiers, never blended

preclinical — animal, cell or mechanistic work — not yet about people

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Summary

SS-31 (elamipretide) is a mitochondria-targeted compound that binds with high affinity to cardiolipin, a phospholipid of the inner mitochondrial membrane required for cristae formation. · pmid:23813215

Mechanism

In rats it protected cristae membranes during renal ischemia and accelerated the recovery of ATP on reperfusion. · pmid:23813215

History

In dogs with advanced heart failure, three months of daily elamipretide raised left ventricular ejection fraction and improved mitochondrial function in cardiomyocytes. · pmid:26839394

Identity

PubChem CID 11764719: Elamipretide, C32H49N9O5, 639.8 g/mol. · pubchem:11764719

CAS registry number 736992-21-5. · pubchem:11764719

IUPAC name: (2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide. · pubchem:11764719


Where the evidence actually sits

Preclinical only100%

Proportion of the 2 claims about SS-31 standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.


Living evidence history

The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. (2013) · preclinicalChronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. (2016) · preclinical20132016

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.


Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for SS-31 yet.


Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work
    • The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. · pmid 23813215 · 2013
    • Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. · pmid 26839394 · 2016

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.